ube2ib Antibody

Introduction to UBE2B Antibody

UBE2B, also known as RAD6B or E2-17kDa, is a member of the ubiquitin-conjugating enzyme family. It facilitates the transfer of ubiquitin to target proteins, marking them for proteasomal degradation or functional modulation . The UBE2B antibody is a monoclonal reagent (clone 1F11) developed for applications such as Western blotting, ELISA, and immune cell studies . Its specificity for human UBE2B makes it valuable for investigating the enzyme’s role in diseases, particularly cancer .

Research Findings on UBE2B in Disease

UBE2B has emerged as a prognostic biomarker and therapeutic target in cancers, notably esophageal carcinoma (ESCA). Key findings include:

Mechanistic Insights

• Pathway Involvement: UBE2B activates oncogenic pathways such as TNF-α/NF-κB signaling, epithelial-mesenchymal transition (EMT), and hypoxia response .

• Immune Modulation: UBE2B expression is linked to altered immune infiltration, including increased CD8+ T cells and macrophages, and reduced Th17 cells in ESCA tumors .

Functional Validation

• Knockdown Studies: Silencing UBE2B in ESCA cell lines suppresses proliferation and migration, confirming its oncogenic role .

• Immune Correlation: UBE2B expression positively correlates with B cell activation and receptor signaling pathways (GO:0050853, p = 0.002) .

Future Directions

UBE2B’s involvement across multiple cancer types highlights its potential as a pan-cancer target. Current research aims to:

• Develop bispecific antibodies or small-molecule inhibitors targeting UBE2B .

• Explore its role in immune tolerance and autoimmunity, given its interaction with Treg-mediated pathways .